Formation of JDC. Promptly after the Effective Date, the Parties will form a Joint Development Committee comprised of three (3) representatives of Ascendis and three (3) representatives of the Licensee for the first Research and Technical Development Plan (and will promptly form a JDC following agreement between the Parties in relation to each additional Research and Technical Development Plan). Ascendis agrees that it shall not have the right to nominate representatives of the Licensee to the JDC notwithstanding its ownership in the Licensee. One representative of the Licensee at the JDC will be selected to act as the chairperson of the JDC. The JDC will meet at least [***] ([***]) times per year during the term of a Research and Technical Development Plan. Such meetings may be conducted by videoconference, teleconference or in person, as agreed by the Parties. The JDC will agree upon the time and location of the meetings. The chairperson, or his or her designee, will circulate an agenda for each meeting approximately [***] before the date scheduled for the meeting, and will include all matters requested to be included on such agenda by either Party. The chairperson, or his or her designee, will take complete and accurate minutes of all discussions occurring at the JDC meetings and all matters decided upon at the meetings except that matters reflecting legal advice of counsel will not be included in such minutes. A copy of the draft minutes of each meeting will be provided to each Party by the chairperson, or his or her designee, after each meeting, and such minutes will be reviewed by the JDC members, any needed changes discussed and final minutes agreed to and provided to each Party within [***] ([***]) days after each meeting unless otherwise agreed. A reasonable number of additional representatives of a Party may attend meetings of the JDC in a non-voting capacity. Each Party is responsible for its personnel and travel costs and expenses associated with attending meetings.
Formation of JDC. Promptly following the Effective Date, the Parties shall form the JDC, and each Party will appoint two of its employees to serve on the JDC. The purpose of the JDC is to oversee, guide, and monitor the conduct of the Joint Development Program under the terms of this JDA. To ensure the success of the Joint Development Program, the JDC will meet regularly and at least quarterly to review the progress towards the objectives of the Joint Development Program. Such meetings may be held in person, or by any means of telecommunications or video conference, as the JDC members deem necessary or appropriate. The JDC will keep minutes of its meetings, including at a minimum who is in attendance, the subject matter discussed or considered, and any action taken. Decisions of the JDC will be made by unanimous approval, with the representatives of Genomatica collectively having one vote and the representatives of T&L collectively having one vote. If the JDC is unable to reach agreement on any matter properly before it, then either Party may, by written notice to the other Party, have such matter referred for resolution pursuant to Section 14.14.
Formation of JDC. 19 SECTION 4.02.
Formation of JDC. Within thirty (30) days after the ---------------- Effective Date (or such later time as may be mutually agreed to by the Parties), the Parties shall establish the JDC. The JDC shall consist of an equal number of representatives of CTI and ORTHO to be agreed upon by the Parties from time to time. Either Party may designate a substitute for a member unable to be present at a meeting. One of the ORTHO members of the JDC, chosen at the sole discretion of ORTHO, along with one of the CTI members of the JDC, chosen at the sole discretion of CTI, shall serve as co-chair of the JDC. Regardless of the number of representatives from each Party on the JDC, each Party shall have one vote on any issue in dispute. Meetings of the JDC shall be held at least quarterly and may be called by either Party with not less than ten (10) business days notice to the other unless such notice is waived, and meetings shall be held at the office of the Party not calling the meeting, unless otherwise agreed. The JDC may be convened, polled or consulted from time to time by means of telecommunication or correspondence. Each Party will disclose to the other proposed agenda items reasonably in advance of each meeting of the JDC. Each Party shall bear its own costs for participation in the JDC.
Formation of JDC. 9 SECTION 2.02.
Formation of JDC. Within thirty (30) days after the Effective Date (or such later time as may be mutually agreed to by the Parties), the Parties shall establish the JDC. The JDC shall consist of an equal number of representatives of Alliance and Schering to be agreed upon by the Parties from time to time. Either Party may designate a substitute for a member unable to be present at a meeting. One member of the JDC, chosen at the sole discretion of Alliance, shall serve as Chairman of the JDC. Regardless of the number of representatives from each Party on the JDC, each Party shall have one vote on any issue. Meetings of the JDC shall be held at least quarterly and may be called by either Party with not less than ten (10) business days notice to the other unless such notice is waived, and meetings shall be held at the office of Schering's Affiliate, Berlex Laboratories, Inc., in New Jersey, unless otherwise agreed. The JDC may be convened, polled or consulted from time to time by means of telecommunication or correspondence. Each Party will disclose to the other proposed agenda items reasonably in advance of each meeting of the JDC. Each Party shall bear its own costs for participation in the JDC.
Formation of JDC. Alteon and OXIS shall form a separate Joint Development Committee (“JDC”). The JDC shall be comprised of *** members *** from Alteon; and *** from OXIS.
Formation of JDC. GTx and Ortho shall form a Joint Development Committee ("JDC"). The JDC shall be comprised of equal numbers (up to three (3) from each Party) of appropriately expert and experienced individuals, with one such person assigned by each Party as such Party's co-chair. Either Party may designate a substitute for a committee member to participate in the event one of that Party's regular committee members is unable to be present at a meeting.
Formation of JDC. Promptly after the Effective Date, GTx and Ipsen shall form a Joint Development Committee (“JDC”) comprised of equal numbers of reasonably qualified representatives of each Party (not to exceed three (3) representatives of each Party) who have expertise in the clinical development, registration and commercialization of pharmaceutical products, with one such person assigned by each Party as such Party’s co-chair (each, a “Co-Chair”). Either Party may designate a substitute for a committee member to participate in the event one of that Party’s regular committee members is unable to be present at a meeting. The formation of the JDC as well as its responsibilities may be amended from time to time by mutual agreement of the Parties.
Formation of JDC. Co-Development Plan; Medical Affairs Plan.
(a) Upon exercise of the Co-Development Option for a Development Compound (each a “Co-Development Compound”), the Parties will form a joint development committee (the “JDC”), comprised of an equal number of representatives from the senior clinical research management of each Party, to review and oversee the Development of such Co-Development Compound, including: (i) establishing and directing the strategy for the worldwide Development of such Co-Development Compound; (ii) creating, reviewing and finalizing a Co-Development Plan for such Co-Development Compound and proposing any revisions to such Co-Development Plan as needed, but no less frequently than annually; (iii) subject to and within the parameters of the Co-Development Plan, (A) overseeing the implementation of the Co-Development Plan (including approval of clinical trial protocols and review of the conduct of clinical trials conducted pursuant to the Co-Development Plan), and (B) reviewing and approving the overall strategy and positioning of all material submissions and filings with the applicable Regulatory Authorities; and (iv) performing such other duties as the Parties may designate.
(b) The JDC will make decisions by consensus. In the event the JDC fails to reach unanimous agreement with respect to a particular matter within its decision-making authority, then either Party may have such matter referred to the heads of development for each Party, who will meet promptly and negotiate in good faith to resolve such matter. If the heads of Development are unable to resolve such matter within thirty (30) days or such longer period of time as they may agree, the matter will be referred to the authorized executive officers of the Parties for resolution. If the disagreement cannot be resolved by such officers, Biogen Idec will have final decision-making authority.
(c) Biogen Idec will prepare, in consultation with PTI and for review by the JDC as described above, a written plan and budget for the co-Development of each Co-Development Compound (a “Co-Development Plan”). For avoidance of doubt, Biogen Idec will have final decision-making rights regarding the content, development, and execution of the Co-Development Plans.
(d) The Parties will also jointly develop and execute a plan for the medical affairs activities supporting each Co-Development Compound both pre- and post-approval (each a “Medical Affairs Plan”). The cost of such activities will be shared pr...
